Lexeo Therapeutics, Inc. (LXEO): who owns it and who trades it
As of Nov 16, 2026, LXEO insiders reported 17 open-market sales worth $752K and no purchases in the last 12 months, with 42% of the sale value made under pre-set 10b5-1 plans. The largest seller was Richard Nolan Townsend (CEO), with $538K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Lexeo Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns LXEO
142 funds and institutions reported LXEO shares worth $418M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Montanova Capital, LLC with 8.6%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Montanova Capital, LLC | 6.38M | 8.62% | $29.7M | +411% |
| Affinity Asset Advisors, LLC | 5.81M | 7.84% | $27M | +15% |
| BlackRock, Inc. | 5.74M | 7.75% | $26.7M | +12% |
| Ra Capital Management, L.P. | 5.00M | 6.75% | $23.3M | No change |
| Frazier Life Sciences Management, L.P. | 4.82M | 6.51% | $22.5M | +9% |
| State Street Corp | 4.35M | 5.88% | $20.3M | +22% |
| Vestal Point Capital, LP | 4.32M | 5.83% | $20.1M | -3% |
| Paradigm Biocapital Advisors LP | 4.18M | 5.64% | $19.4M | -32% |
| Jupiter Topco LLC | 3.95M | 5.34% | $18.4M | – |
| Orbimed Advisors LLC | 3.95M | 5.33% | $18.4M | +10% |
| Citadel Advisors LLC | 3.90M | 5.26% | $18.1M | +2% |
| Vanguard Capital Management LLC | 3.13M | 4.22% | $14.6M | +4% |
| Millennium Management LLC | 2.83M | 3.82% | $13.2M | +76% |
| Nantahala Capital Management, LLC | 2.60M | 3.51% | $12.1M | +117% |
| Woodline Partners LP | 2.50M | 3.38% | $11.6M | -9% |
| Balyasny Asset Management L.P. | 2.41M | 3.26% | $11.2M | +52% |
| Goldman Sachs Group Inc | 2.15M | 2.90% | $10M | +10% |
| 683 Capital Management, LLC | 1.88M | 2.53% | $8.7M | +56% |
| Geode Capital Management, LLC | 1.75M | 2.36% | $8.1M | +15% |
| ADAR1 Capital Management, LLC | 1.57M | 2.11% | $7.3M | +7% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, LXEO insiders reported $0 of open-market purchases and $752K of sales. 42% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Louis Edward Tamayo | CFO | Sale | 4,117 | $4.91 | $20.2K | Form 4 |
| Aug 18, 2026 | Richard Nolan Townsend | CEO | Sale | 3,345 | $4.95 | $16.6K | Form 4 |
| Aug 18, 2026 | Jose Manuel Otero | Chief Operating Officer | Sale | 1,304 | $4.96 | $6.5K | Form 4 |
| Jul 1, 2026 | Louis Edward Tamayo | CFO | Sale | 4,641 | $4.49 | $20.8K | Form 4 |
| Jul 1, 2026 | Jose Manuel Otero | Chief Operating Officer | Sale | 4,666 | $4.48 | $20.9K | Form 4 |
| Jul 1, 2026 | Narinder Pal Bhalla | Chief Medical Officer | Sale | 22,306 | $4.42 | $98.6K | Form 4 |
| Jul 1, 2026 | Richard Nolan Townsend | CEO | Sale | 25,947 | $4.48 | $116K | Form 4 |
| May 18, 2026 | Jose Manuel Otero | Chief Operating Officer | Sale | 1,302 | $5.07 | $6.6K | Form 4 |
| May 18, 2026 | Richard Nolan Townsend | CEO | Sale | 3,342 | $5.06 | $16.9K | Form 4 |
| Apr 6, 2026 | Richard Nolan Townsend | CEO | Sale plan | 55,000 | $5.69 | $313K | Form 4 |
| Feb 18, 2026 | Jose Manuel Otero | Chief Operating Officer | Sale | 3,016 | $6.40 | $19.3K | Form 4 |
| Feb 18, 2026 | Richard Nolan Townsend | CEO | Sale | 10,173 | $6.38 | $64.9K | Form 4 |
| Nov 18, 2025 | Jose Manuel Otero | Chief Operating Officer | Sale | 721 | $9.27 | $6.7K | Form 4 |
| Nov 18, 2025 | Richard Nolan Townsend | CEO | Sale | 1,127 | $9.27 | $10.4K | Form 4 |
| Nov 18, 2025 | Eric Adler | Chief Medical Officer | Sale | 615 | $9.27 | $5.7K | Form 4 |
| Nov 18, 2025 | Tai Sandi See | Chief Development Office | Sale | 386 | $9.27 | $3.6K | Form 4 |
| Nov 18, 2025 | Jenny Robertson | Chief Legal Officer | Sale | 549 | $9.27 | $5.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Richard Nolan Townsend | Chief Executive Officer, Director | – | $538K | Aug 18, 2026 |
| Narinder Pal Bhalla | Chief Medical Officer | – | $98.6K | Jul 1, 2026 |
| Jose Manuel Otero | Chief Operating Officer | – | $60K | Aug 18, 2026 |
| Louis Edward Tamayo | Chief Financial Officer | – | $41.1K | Aug 18, 2026 |
| Eric Adler | Chief Medical Officer | – | $5.7K | Nov 18, 2025 |
| Jenny Robertson | Chief Legal Officer | – | $5.1K | Nov 18, 2025 |
| Tai Sandi See | Chief Development Officer | – | $3.6K | Nov 18, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LXEO short interest
Very high short interest. 20.8% of LXEO shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 29%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 17.04M LXEO shares were sold short, 20.8% of the shares outstanding, down 2.9% from the report before. At the average daily volume of 1.34M shares, buying them all back would take about 12.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 17.04M | 20.77% | -3% | 1.34M | 12.7 |
| Oct 15, 2026 | 17.55M | 21.39% | -9% | 1.75M | 10.0 |
| Sep 30, 2026 | 19.25M | 23.46% | -7% | 2.13M | 9.0 |
| Sep 15, 2026 | 20.63M | 25.14% | +1% | 616,778 | 33.4 |
| Aug 31, 2026 | 20.49M | 24.97% | No change | 763,910 | 26.8 |
| Aug 14, 2026 | 20.48M | 24.96% | +20% | 1.04M | 19.8 |
| Jul 31, 2026 | 17.05M | 23.02% | +4% | 1.01M | 16.9 |
| Jul 15, 2026 | 16.35M | 22.07% | +1% | 836,123 | 19.6 |
| Jun 30, 2026 | 16.13M | 21.77% | +14% | 1.15M | 14.0 |
| Jun 15, 2026 | 14.09M | 19.02% | +2% | 748,947 | 18.8 |
| May 29, 2026 | 13.78M | 18.59% | +4% | 793,543 | 17.4 |
| May 15, 2026 | 13.21M | 17.83% | +1% | 702,022 | 18.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Lexeo Therapeutics company events
Lexeo Therapeutics filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Sep 29, 2026.
- Sep 29, 2026DealCompletion of Acquisition or Disposal of Assets. Filing
- Sep 22, 2026AgreementLexeo Therapeutics, Inc. entered into an Agreement and Plan of Merger with Mantle Therapeutics Inc., Magma Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company, and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity… Filing
- Aug 12, 2026AnnouncementThe Company posted on its website an updated corporate presentation. Filing
- Jun 29, 2026VoteReported shareholder vote results. Filing
- Jun 15, 2026AnnouncementBelow is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. Filing
- May 11, 2026AnnouncementThe Company posted on its website an updated corporate presentation. Filing
- Apr 30, 2026LeadershipDr. Laura Sepp-Lorenzino was appointed to the board of directors of Lexeo Therapeutics, Inc. Filing
- Mar 30, 2026AnnouncementThe Company posted on its website an updated corporate presentation. Filing
- Feb 5, 2026LeadershipLexeo Therapeutics, Inc. entered into a Transition and Consulting Agreement with Dr. Adler, effective February 1, 2026, pursuant to which Dr. Adler stepped down from his role of Head of Research and will continue to provide certain advisory services to the Company until the earlier of (i) July 31… Filing
- Jan 27, 2026LeadershipLexeo Therapeutics, Inc. announced that the Board of Directors of the Company appointed Jose Manuel Otero, Ph.D., the Company’s current Chief Technical Officer, to serve as Chief Operating Officer of the Company, effective as of January 2, 2026. Filing
- Jan 12, 2026AnnouncementBelow is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Lexeo Therapeutics financials
Famous investors that hold LXEO
5 of the 50 well-known investors we track reported holding LXEO in their latest 13F filing. The largest position is Ken Griffin's, worth $14.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 4.24M | $14.3M | 0.0% | +9% |
| Israel Englander · Millennium Management | Q3 2026 | 3.78M | $12.8M | 0.0% | +33% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 447,197 | $1.5M | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 371,522 | $1.3M | 0.0% | +48% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 114,322 | $386K | 0.0% | No change |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 16 filings named LXEO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 10.0% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 7.2% |
| Nov 16, 2026 | Vestal Point Capital, LP | 13G/A | 6.3% |
| Nov 16, 2026 | OrbiMed Advisors LLC | 13G/A | 3.9% |
| Nov 16, 2026 | Paradigm BioCapital Advisors LP | 13G/A | 0.0% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 10.0% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 7.2% |
| Nov 16, 2026 | OrbiMed Advisors LLC | 13G/A | 3.9% |
| Nov 16, 2026 | Paradigm BioCapital Advisors LP | 13G/A | 0.0% |
| Nov 16, 2026 | Vestal Point Capital, LP | 13G/A | 6.3% |
| Nov 13, 2026 | Affinity Asset Advisors, LLC | 13G/A | 9.8% |
| Nov 13, 2026 | Affinity Asset Advisors, LLC | 13G/A | 9.8% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.4% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.4% |
| Oct 13, 2026 | JPMORGAN CHASE & CO. | 13G | 5.5% |
| Oct 13, 2026 | JPMORGAN CHASE & CO. | 13G | 5.5% |
Questions about Lexeo Therapeutics, Inc. (LXEO) stock
Who owns the most LXEO stock?
The largest reported owner of Lexeo Therapeutics, Inc. (LXEO) is Montanova Capital, LLC, with 8.6% of the company. In total, 142 funds and institutions reported holding LXEO at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are LXEO insiders buying or selling?
In the last 12 months, LXEO insiders reported no open-market purchases and 17 sales worth $752K. The latest trade was on Aug 18, 2026. See every trade.
What is the short interest in LXEO?
As of Oct 30, 2026, 17.04M LXEO shares were sold short, 20.8% of the shares outstanding, down 2.9% from the report before. At the average daily volume of 1.34M shares, buying them all back would take about 12.7 trading days (days to cover). See the history.
Which famous investors hold LXEO?
5 of the 50 well-known investors we track reported LXEO in their latest 13F filing, including Ken Griffin, Israel Englander, Steve Cohen. The largest position is worth $14.3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.